Company / Operating Income
Charles River Laboratories Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$25.2M
FY2025
5-year range
$25.2M / $589.9M
FY2021-FY2025
Trend
-88.9%
vs FY2024
Sector context
#96 of 156
Health Care
What the data says
At $25M, Charles River Laboratories's operating income ranks #96 of 156 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from $25M in FY2025 to $590M in FY2023.
Based on SEC 10-K filings.
$25M in FY2025 with a 5-year CAGR of -40.3%.
Declined from $590M to $25M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -61.3%
- 5-Year CAGR
- -40.3%
- 10-Year CAGR
- -
Sector benchmark
#96 of 156 in Health CareTop 62% of 156This company $25.2M Sector average $733.1M
▼
-96.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -40.3%, indicating a declining trend.
- In FY2025, operating income decreased 88.9% year-over-year.
- Ranks #96 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.2M | -88.9% |
| FY2024 | $227.3M | -61.5% |
| FY2023 | $589.9M | +36.3% |
| FY2022 | $432.7M | +23.2% |
| FY2021 | $351.2M | +6.0% |
| FY2020 | $331.4M | +15.0% |
| FY2019 | $288.3M | -13.0% |
| FY2018 | $331.4M | +15.0% |
| FY2017 | $288.3M | +21.4% |
| FY2016 | $237.6M | +56.9% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026